Skip to content
Start consultationStart
Weight loss · Ireland

Tirzepatide in Ireland, online

An EU-licensed doctor reviews your case and, if eligible, issues an electronic prescription you can collect at a pharmacy in Ireland.

From€25/ 28 days

Consultation price. The medicine is paid at your pharmacy.

  • Prescription only, if a doctor approves
  • Doctor-reviewed renewals
  • Full refund if not approved
Start consultation
Tirzepatide

Licensed EU doctors

Every case read by a registered doctor.

Reply in under 2 hours

On average, in writing, no video call.

Pay only if approved

Not approved? Refunded in full, automatically.

Rated excellent on Trustpilot

4.8 from 540+ independent reviews.

Valid across the EU

E-prescription accepted at EU pharmacies.

Local facts

Tirzepatide consultations in Ireland

Available toResidents of Ireland
LanguagesSpanish and English
Doctor replyUnder 2 hours on average
Collected atPharmacies in Ireland · e-prescription (PDF)
About the medicine

What it is and how it works

Tirzepatide is a dual receptor agonist. It acts on the GLP-1 and GIP gut-hormone receptors at the same time. In clinical trials this translates into larger average weight loss than mono-agonist GLP-1s in adults with obesity.

It's a chronic treatment for as long as it's beneficial and safe: the doctor reviews your response every 3 months and decides with you whether to continue, adjust or stop. Discontinuation is gradual and paired with a maintenance plan.

Who it is for

  • Adults who meet the BMI criteria for weight management, and type 2 diabetes.
  • One injection under the skin, once a week, on the same day each week.

Safety summary

Nausea and diarrhoea are very common; severe stomach pain can signal pancreatitis.

Read the safety summary
Pricing

One consultation, one clear price

You pay for the doctor's consultation. If a prescription is issued, the medicine is paid at your own pharmacy.

  • Consultation reviewed by an EU-licensed doctor
  • Private follow-up in the in-app chat
  • Full refund if the doctor does not approve
Plan or one-off

Weight loss

Monthly planCancel anytime€25/ 28 daysOne-off28-day treatment€35once
  • First consultation included
  • Renewals reviewed by your doctor
  • Ongoing care in your private chat
  • Cancel anytime
Start consultation

Full refund if a review is not approved

FAQs

Your questions answered

Tirzepatide16 questions
How is tirzepatide different from a classic GLP-1?
Tirzepatide is a dual receptor agonist (GLP-1 and GIP) which, in trials, shows larger average weight loss than mono-agonist GLP-1s in adults with obesity.
Not necessarily. It is a chronic treatment while it is beneficial and safe: the doctor reviews response every 3 months and decides with you whether to continue, adjust or stop. Discontinuation must be gradual and paired with a maintenance plan.
More questions
History of pancreatitis, gallbladder issues, family history of medullary thyroid cancer, pregnancy or plans to conceive, and current medication. Recent labs are also reviewed if provided.
Quarterly medical review through the private in-app chat, dose adjustments if side effects arise, and a new electronic prescription valid in any EU pharmacy when applicable.
Yes. Tirzepatide is the active ingredient, and Mounjaro is the brand name it is sold under in the European Union. In the United States the same molecule is also sold as Zepbound for weight management, but Zepbound is not authorised in the EU, so an EU prescription for tirzepatide will be written for Mounjaro. The European Medicines Agency authorised Mounjaro on 15 September 2022, and its licence now covers both type 2 diabetes and weight management in adults who meet the BMI criteria.
Weight tends to come back. In SURMOUNT-4, adults who had already lost a mean of 20.9% over a 36-week lead-in were randomly assigned either to keep taking tirzepatide or to switch to placebo. Between week 36 and week 88 the continued group changed by a further -5.5%, while the placebo group regained 14.0%. At week 88, 89.5% of the continued group had kept at least 80% of the weight lost during the lead-in, compared with 16.6% of the placebo group. Stopping is a decision to make with your prescriber.
No. The product information lists 5 mg, 10 mg and 15 mg as the recommended maintenance doses, so 5 mg and 10 mg are licensed end points in their own right and not only steps on the way up. In SURMOUNT-1 the 5 mg group had a mean body-weight change of -15.0% at 72 weeks, the 10 mg group -19.5% and the 15 mg group -20.9%. Gastrointestinal side effects were also more frequent at higher doses. Your prescriber decides where to stop, based on how you respond and how well you tolerate each step.
Write to your doctor in the private chat in your account: describe what you notice and when it started. The doctor can adjust the plan, pause it or suggest another option. If you have severe symptoms such as difficulty breathing, swelling of the face or chest pain, call 112 or go to an emergency department straight away.
It depends on what you take. List every medicine, supplement and herbal product in the questionnaire, including ones you use only occasionally. The doctor checks for interactions before prescribing, and your pharmacist checks again when you collect Tirzepatide.
The doctor can consider another weight-management medicine authorised in the EU, or a plan built on nutrition and activity alone. Some people are better served by an in-person obesity clinic or by their own doctor, and the doctor explains why when that is the case.
Before each renewal the doctor reviews your weight, side effects and how you feel, and decides whether to continue, change the dose or stop. Changes are never automatic. You can also write in the private chat between reviews.
Yes. Hi-Doctor runs 100 % online across the EU, so if you live in Ireland you can fill in the questionnaire and receive the medical review without travelling. The electronic prescription issued by the licensed doctor is valid in any EU pharmacy under Directive 2011/24/EU; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.
Adults with BMI ≥ 30, or ≥ 27 with comorbidities (hypertension, type-2 diabetes, dyslipidaemia). The doctor reviews your history, current medication and goals before proposing any treatment. It is not a cosmetic programme.
The private electronic prescription (Receta Médica Privada Electrónica) is issued by a licensed doctor in Spain. It is a PDF carrying every field required by EU Directive 2011/24/EU (patient, prescriber with country of registration, active ingredient, dose), which makes it legally recognised across all 27 EU member states. In Spanish pharmacies it is dispensed from the QR; outside Spain, the pharmacist dispenses the locally marketed equivalent of the same active ingredient.
1) Fill in an online medical questionnaire in about 4 minutes. 2) The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; sexual health is €35 per consultation and a skin consultation is €40. 3) An EU-licensed doctor reviews your case and, if appropriate, issues an electronic prescription. 4) Collect it at any EU pharmacy. If the review is not approved, the applicable fee is refunded in full.
The plan is €25/month for weight loss or €15/month (billed €45 every 90 days) for hair growth; a one-off sexual-health consultation is €35 and a skin consultation covering acne, rosacea, melasma and ageing skin is €40. Each includes a licensed doctor's review and an electronic prescription if approved. If the review is not approved, the applicable fee is refunded in full. Medication is paid for separately at the pharmacy at the price it sets.
Behind the scenes

How your doctor decides

Your answers

A licensed doctor reads your full questionnaire.

Medical judgement

The decision is clinical, never an algorithm.

Clear outcome

Approved with an e-prescription, or refunded in full.

Also for Weight loss

Related medicines

Medicine information and safety

How does Tirzepatide work?

Copies two gut hormones. Tirzepatide activates the receptors for two natural gut hormones, GIP and GLP-1, which the body releases after eating. The EU product information describes it as a long acting GIP and GLP-1 receptor agonist that binds both receptors with high affinity.

Turns down appetite signals. Both of those receptors also sit in the brain areas that regulate appetite. Clinical studies cited in the product information report that tirzepatide reduces energy intake and appetite by increasing feelings of satiety and fullness, and by decreasing feelings of hunger.

Slows the stomach, steadies glucose. Tirzepatide delays gastric emptying, so food leaves the stomach more slowly after a meal. It also increases insulin release in a glucose dependent way and lowers glucagon. The weight change comes mainly from eating less, and is mostly a loss of fat mass.

How to use Tirzepatide

Pick one day each week. Tirzepatide is injected once a week, at any time of day, with or without food. Pick a day that is easy to remember. You can change the day later as long as three days separate two doses.

Store pens in the fridge. Unused pens are kept in a refrigerator between 2 and 8 degrees Celsius, in the original carton so light cannot reach them, and must never be frozen. A pen that has been frozen must not be used.

Check the pen before use. Look at the liquid before you inject. It should be clear and free of particles or discolouration. Discard the pen if you can see anything floating in it, if it looks discoloured, or if it is out of date.

Inject into tummy, thigh or arm. Tirzepatide goes under the skin of the abdomen, the thigh or the upper arm. The back of the upper arm needs another person to do the injection. Read the instructions for use packed with the pen first.

Rotate the spot every week. Injection sites should be rotated with each dose, so the same patch of skin is not used week after week. If you also inject insulin, use a different site for each of the two medicines.

Missed dose: the four day rule. If you remember within four days, inject then and return to your usual schedule. If more than four days have passed, skip that dose and take the next one on the normal day. Never inject two doses to catch up.

Know how long a pen lasts. Single-dose pens and vials may be kept out of the refrigerator for up to 21 cumulative days below 30 degrees Celsius, then discarded. A multi-dose KwikPen holds four weekly doses and is thrown away 30 days after first use.

Keep the diet and activity going. Tirzepatide is licensed as an addition to a reduced-calorie diet and increased physical activity, not as a replacement for them. Every trial result quoted on this page comes from people doing both alongside the weekly injection.

Common side effects

Stop and get urgent medical help if (seek medical help immediately): Severe, persistent pain in the stomach area, with or without nausea and vomiting, which can signal pancreatitis, Breathing problems, or rapid swelling of the lips, tongue or throat, Difficulty swallowing together with a fast heartbeat, which can signal a severe allergic reaction, Vomiting or diarrhoea so severe or so lasting that you cannot keep fluids down, because dehydration can damage the kidneys, Pain in the upper right of the tummy with fever, or yellowing of the skin or eyes, Shakiness, sweating and confusion, if you also take insulin or a sulfonylurea for diabetes

Very common (very common (≥1/10)): Feeling sick (nausea), most often while the dose is being increased, Diarrhoea, usually mild or moderate, and easing over time

Common (common (≥1/100 to <1/10)): Vomiting, Constipation, Pain in the stomach area (abdomen), Indigestion, bloating, burping, wind or acid reflux, Tiredness, weakness or generally feeling unwell, Injection site reactions, most often redness and itching, Dizziness, or low blood pressure, A faster heart rate, Hair loss, Hypersensitivity reactions such as rash and dermatitis, Raised lipase or amylase on blood tests

Uncommon (uncommon (≥1/1,000 to <1/100)): Gallstones, or inflammation of the gallbladder (cholecystitis), Acute pancreatitis, which is inflammation of the pancreas, Pain at the injection site, Raised blood calcitonin, seen only on a blood test, Delayed stomach emptying, listed as uncommon in UK labelling

Rare (rare (≥1/10,000 to <1/1,000)): Anaphylactic reaction, a sudden and severe whole-body allergic reaction, Angioedema, deep swelling under the skin, often of the face or throat

Do not use Tirzepatide if

  • You have ever had an allergic reaction to tirzepatide or to any other ingredient in the pen.
  • You are pregnant or planning a pregnancy. Tirzepatide is not recommended in pregnancy or in women of childbearing potential not using contraception.
  • You are breastfeeding. A risk to the infant cannot be excluded, so the prescriber weighs continuing feeding against continuing treatment.
  • You have had pancreatitis. Tirzepatide has not been studied in these patients and should be used with caution.
  • You have severe gastrointestinal disease, including severe gastroparesis. Tirzepatide has not been studied in this group.
  • You have proliferative diabetic retinopathy, diabetic macular oedema, or retinopathy needing acute treatment. Caution and monitoring apply.
  • You are under 18 years old. Safety and efficacy for weight management have not been established below that age.
  • You have severe kidney impairment, end stage renal disease, or severe liver impairment. Experience is limited, so caution applies.
  • You are booked for general anaesthesia or deep sedation. Tell the team you take tirzepatide, because pulmonary aspiration has been reported.

Medicines and substances that interact

  • Oral medicines in general: Tirzepatide delays gastric emptying, so tablets can be absorbed more slowly, especially at the start. Most oral medicines need no dose change. The prescriber reviews your full list.
  • Warfarin, digoxin and other narrow therapeutic index drugs: Absorption can shift when tirzepatide is started or the dose is increased. The prescriber monitors you more closely at initiation and after each dose increase.
  • Sulfonylureas (for example gliclazide): Combined use raises the risk of low blood sugar in people with type 2 diabetes. The prescriber may reduce the sulfonylurea dose and ask for blood glucose self-monitoring.
  • Insulin: Combined use raises hypoglycaemia risk; clinically significant lows occurred in 14 to 19 percent. The prescriber reduces insulin stepwise and arranges blood glucose self-monitoring.
  • Combined oral contraceptives: A single 5 mg dose reduced ethinylestradiol peak level by 59 percent and delayed it four hours. EU labelling requires no dose change. UK labelling advises adding a barrier method for four weeks.
  • Paracetamol: A single 5 mg dose halved the paracetamol peak level and delayed it by one hour. No dose adjustment needed. Overall exposure was unchanged after four consecutive weekly doses.
  • Oral medicines where rapid onset matters: Delayed gastric emptying can postpone the effect of a tablet you need to work quickly. The prescriber considers timing, a non-oral route, or an alternative medicine.

References

  1. Mounjaro (tirzepatide): European public assessment report, medicine overview European Medicines Agency, 2022
  2. Mounjaro: Annex I Summary of Product Characteristics European Commission Union Register of Medicinal Products, 2024
  3. Mounjaro KwikPen 5 mg solution for injection in pre-filled pen: Summary of Product Characteristics electronic medicines compendium (emc), 2026
  4. Mounjaro KwikPen 15 mg solution for injection in pre-filled pen: Summary of Product Characteristics electronic medicines compendium (emc), 2026
  5. Mounjaro KwikPen 5 mg: Patient Information Leaflet electronic medicines compendium (emc), 2026
  6. Tirzepatide (Mounjaro): NHS medicines A to Z NHS, 2026
  7. SURMOUNT-1: Tirzepatide once weekly for the treatment of obesity New England Journal of Medicine, 2022
  8. SURMOUNT-2: Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes The Lancet, 2023
  9. SURMOUNT-4: Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity JAMA, 2024
  10. STEP 1: Once-weekly semaglutide in adults with overweight or obesity New England Journal of Medicine, 2021
  11. SCALE Obesity and Prediabetes: a randomized, controlled trial of 3.0 mg of liraglutide in weight management New England Journal of Medicine, 2015
  12. XENDOS: XENical in the prevention of Diabetes in Obese Subjects, a 4-year randomised study Diabetes Care, 2004
  13. Wegovy 2.4 mg FlexTouch solution for injection: Summary of Product Characteristics electronic medicines compendium (emc), 2026
  14. Saxenda 6 mg/mL solution for injection: Summary of Product Characteristics electronic medicines compendium (emc), 2026
  15. Xenical 120 mg hard capsules: Summary of Product Characteristics electronic medicines compendium (emc), 2026
  16. CIMA: Mounjaro presentations, marketing and prescription status in Spain AEMPS (Spanish Agency of Medicines and Medical Devices), 2026
  17. MOUNJARO (tirzépatide), obésité: avis de la Commission de la Transparence Haute Autorité de Santé, 2025
  18. Obésité: prise en charge de WEGOVY et MOUNJARO à partir du 15 juin 2026, sous conditions VIDAL, reporting the arrêté published in the Journal officiel, 2026
  19. Tirzepatide (Mounjaro): monograph and reimbursement status in Belgium BCFI / CBIP, Belgian Centre for Pharmacotherapeutic Information, 2024
  20. Find a Medicine: authorised medicines database Health Products Regulatory Authority (Ireland), 2026
  21. Medicijnkosten.nl: medicine reimbursement database Zorginstituut Nederland, 2026
  22. INFOMED: base de dados de medicamentos de uso humano INFARMED (Portugal), 2026

Also available in

Semaglutide
Semaglutide
Ozempic
Ozempic
Wegovy
Wegovy
Online doctor by city

Also available in

DublinCorkLimerickGalway

Start your treatment journey

A doctor replies in under 2 hours on average.

Start consultationNo charge unless a doctor approves your treatment.
All content on this page has been medically reviewed by: Dr. Alejandro Infante, General medicine, on 27 July 2026. Registration: 080869277 View profile

Pay nothing if a doctor doesn't approve your treatment. Every consultation is fully refundable. How refunds work